Teleflex to sell trio of business lines in deals totalling over $2bn
Teleflex is selling its acute care, interventional urology, and original equipment manufacturer (OEM) businesses in two separate deals totalling over $2bn as part of the company’s broader portfolio optimisation strategy.
UK-based Intersurgical is acquiring Teleflex’s acute care and interventional urology business lines for $530m. Meanwhile, Teleflex’s OEM business is being picked up by private equity firms Montagu and Kohlberg in a carveout deal worth around $1.5bn.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Teleflex’s products within the segments include intermittent catheters in urology and airway management systems in acute care, while its OEM business is focused on assembling tools used in areas such as catheter-based interventions and surgical applications.
Investor sentiment of the latest actions appears positive. Following the announcement of the divestments on 9 December, Teleflex’s shares on the New York Stock Exchange (NYSE) rose by almost 10% to a $131.25 per share close, up from $119.82 the previous day. Teleflex has a market cap of $5.8bn.
Both deals are expected to close by H2 2026 pending customary regulatory approvals and other closing conditions.
According to Liam Kelly, Teleflex’s CEO, the selloffs are expected to establish the company as a “more focused” medical technologies leader, with complementary businesses in vascular access, interventional, and surgical, and a simplified global operating model and manufacturing footprint.
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Further, following these transactions, Teleflex will have increased flexibility to invest in innovation and compete in these priority markets,” Kelly added.
The plans to focus on the areas mentioned by Kelly are seemingly borne out in Teleflex’s most recent financials. In the nine months ended September 28 2025, the lion’s share of Teleflex’s revenue stemmed from the aforementioned business segments. And for Teleflex’s interventional urology and OEM lines, profits were down by 11% and 13.9%, respectively, versus the same period of 2024, suggesting a waning focus. What remains unclear, however, is what effect the selloffs will have on Teleflex’s previously announced intent to split its business in two.
In February 2025, Teleflex announced plans to split its business into two independently traded entities, with a completion date set for mid-2026. At the time, the company said that the business lines that are now being sold off would be grouped under a new standalone business called Teleflex NewCo, with Teleflex’s vascular access, interventional, and surgical businesses grouped under a new entity called RemainCo.
Medical Device Network has reached out to Teleflex for comment on its outlook for the mooted Teleflex NewCo business.
Coinciding with the split announcement, Teleflex completed the acquisition of Biotronik’s vascular intervention business unit for around €760m ($792m). At the time, Teleflex highlighted that the new business, which will sit under RemainCo post-split, will expand the company interventional portfolio to include vascular intervention devices such as drug-coated balloons, drug-eluting stents, and balloon catheters.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Medical Device Network Excellence Awards - Nominations Closed
Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact
Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis Systemand leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.
Content Original Link:
" target="_blank">
